会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Bone replacement material comprising crystalline phases
    • 包含结晶相的骨置换材料
    • US08182832B2
    • 2012-05-22
    • US12424353
    • 2009-04-15
    • Georg BergerAndrea SpitzerChristian JägerJutta PauliRenate Gildenhaar
    • Georg BergerAndrea SpitzerChristian JägerJutta PauliRenate Gildenhaar
    • A61F2/28
    • C03C3/16A61L24/02A61L27/12A61L27/50A61L2430/02C03C3/062
    • The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1−xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.1 to 20% by weight of a substance selected from the group consisting of Na2CaP2O7, K2CaP2O7, Ca2P2O7 and mixtures thereof is contained as a secondary crystal phase, the X-ray amorphous phases contained besides the main crystal phase jointly making up 0.1 to 70% by weight relative to the total weight of the finished material.
    • 本发明涉及可用作生物活性骨置换材料和作为生物技术中的底物材料的具有高溶解度的X射线非晶态材料。 包含结晶和X射线无定形相的新材料的特征在于根据31P-NMR测量,其包含正磷酸盐和Q1-二磷酸盐基团的Q0-组,正磷酸盐或Q0-基团组成70-99.9重量% 相对于成品材料的总磷含量和相对于成品材料的总磷含量为0.1〜30重量%的二磷酸盐或Q1-基团的总磷含量,并且根据X射线衍射测量值和相对于总量 在骨替代材料中含有30〜99.9重量%的由Ca2K1-xNa1 + x(PO4)2构成的主晶相,x = 0.1〜0.9,0.1〜20重量% 含有选自Na 2 CO 3 P 2 O 7,K 2 Ca 2 O 7,Ca 2 P 2 O 7的物质及其混合物作为二级结晶相,除了主晶相外含有的X射线非晶相共重量为0.1-70% t相对于成品材料的总重量。
    • 3. 发明授权
    • Bone replacement material comprising crystalline and X-ray amorphous phases
    • 骨替代材料包括晶体和X射线非晶相
    • US07547448B2
    • 2009-06-16
    • US10689219
    • 2003-10-20
    • Georg BergerAndrea SpitzerChristian JägerJutta PauliRenate Gildenhaar
    • Georg BergerAndrea SpitzerChristian JägerJutta PauliRenate Gildenhaar
    • A61F2/28
    • C03C3/16A61L24/02A61L27/12A61L27/50A61L2430/02C03C3/062
    • The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the ortho-phosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1−xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.1 to 20% by weight of a substance selected from the group consisting of Na2CaP2O7, K2CaP2O7, Ca2P2O7 and mixtures thereof is contained as a secondary crystal phase, the X-ray amorphous phases contained besides the main crystal phase jointly making up 0.1 to 70% by weight relative to the total weight of the finished material.
    • 本发明涉及可用作生物活性骨置换材料和作为生物技术中的底物材料的具有高溶解度的X射线非晶态材料。 包括结晶和X射线非晶相的新材料的特征在于,根据31P-NMR测量,其包含正磷酸盐和Q 1组二磷酸酯的QO-基团,正磷酸盐或QO-基团占70-99.9% 相对于成品材料的总磷含量和相对于成品材料的总磷含量为0.1〜30重量%的二磷酸盐或Q1-基团的总磷含量,根据X射线衍射测定,相对于 成骨材料的总重量为30〜99.9重量%的由Ca2K1-xNa1 + x(PO4)2组成的主晶相,其中x = 0.1〜0.9,包含在骨置换材料中,0.1〜20重量% 含有选自Na 2 CO 3 O 2 O 7,K 2 Ca 2 O 7,Ca 2 P 2 O 7的物质及其混合物作为二级结晶相,主晶相以外的X射线非晶相共同构成0.1〜70重量% 相对于成品材料的总重量。
    • 5. 发明授权
    • Powder mixture for resorbable calcium phosphate biocements
    • 用于可再吸收的磷酸钙生物活性剂的粉末混合物
    • US07223420B2
    • 2007-05-29
    • US10689221
    • 2003-10-20
    • Georg BergerHeidi MarxChristian JägerJutta Pauli
    • Georg BergerHeidi MarxChristian JägerJutta Pauli
    • A61L24/00A61K9/14A61K33/42A61K33/08A61K33/00A01N59/26A01N59/06A01N59/00
    • A61L24/001A61L27/56A61L2430/02
    • The present invention relates to a powder mixture for resorbable calcium phosphate biocements, which mixture consists of 40–99% by volume of powder having a particle size of 0.1–10 μm, 1–20% by volume of powder having a particle size of 10–43 μm and 0–59% by volume of powder having a particle size of 43–315 μm, which powder is obtained by grinding the spontaneously crystallizing melts of a material comprising crystalline and X-ray amorphous phases, which material a) according to 31P-NMR measurements, contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 65 to 99.9% by weight relative to the total phosphorus content of the powder mixture and the diphosphates or Q1-groups making up 0.1 to 35% by weight relative to the total phosphorus content of the powder mixture, and b) according to X-ray diffractometric measurements and relative to the total weight of the powder mixture, contains 35 to 99.9% by weight of a main crystal phase consisting of various Ca-orthophosphates and 0.1 to 20% by weight of a secondary crystal phase consisting of various Ca-diphosphates and chain phosphates, and c) besides the main crystal phase, contains an X-ray amorphous phase which in total makes up 0.1 to 65% by weight relative to the total weight of the powder mixture.
    • 本发明涉及可再吸收的磷酸钙生物聚合物的粉末混合物,该混合物由40-99体积%的粒径为0.1-10μm的粉末,1-20体积%的粒径为10的粉末组成 -43μm和0-59体积%的粉末,其粒径为43-315μm,粉末通过研磨包含结晶和X射线非晶相的材料的自发结晶熔体获得,该材料a)根据 P-NMR测量包含正磷酸盐,正磷酸盐或正好磷酸盐的正二磷酸盐和Q 1 - 亚基的Q 0 - 相对于粉末混合物的总磷含量为65至99.9重量%,相对于该粉末混合物的二磷酸盐或Q 1个亚组为0.1至35重量% 粉末混合物的总磷含量,和b)根据X射线衍射测量和相对于粉末混合物的总重量,c 包含35〜99.9重量%的由各种正磷酸钙组成的主晶相和0.1〜20重量%的由各种Ca-二磷酸酯和链磷酸酯组成的二次相晶相,以及c)除了主晶相外,还含有 X射线非晶相,相对于粉末混合物的总重量,其总重量为0.1〜65重量%。
    • 8. 发明授权
    • Method for producing a bioactive bone cement and bone cement kit
    • 生物活性骨水泥和骨水泥试剂盒的生产方法
    • US07109254B2
    • 2006-09-19
    • US10480886
    • 2002-06-14
    • Wolf-Dieter MüllerEmil NagelGeorg Berger
    • Wolf-Dieter MüllerEmil NagelGeorg Berger
    • A61K6/08A61K6/83C08K5/52C08K3/16C08K3/20C08K3/22
    • A61L24/0084A61L24/0089A61L27/446A61L27/46A61L2430/02C08L33/12
    • A method for producing a bioactive bone cement and a bone cement kit for anchoring artificial joints and for filling out bone defects. The method avoids polymerization-linked by-products and disadvantageous effects, while at the same time providing the bone cement with long-term stability. The inventive method uses a monomer-free polymethylmethacrylate, which is mixed with a suitable non-toxic solvent, and a bioactive, vitreous-crystalline material with a particle size ranging from >20 to 200 μm, having 15–45 wt. % CaO, 40–45 wt. % P2O5, 10–40 wt. % ZrO2 and 0.7–3.5 wt. % fluoride, having apatite and calcium zircon phosphate as main crystal phases and a glass phase as an auxiliary component until a flowable mixture is obtained. The invention also relates to a bone cement kit having said components.
    • 生物活性骨水泥的制造方法和用于锚定人造关节并填充骨缺损的骨水泥试剂盒。 该方法避免了与聚合有关的副产物和不利影响,同时为骨水泥提供长期的稳定性。 本发明的方法使用与合适的无毒溶剂混合的无单体聚甲基丙烯酸甲酯和粒度范围> 20至200μm的生物活性玻璃态结晶材料,其具有15-45wt。 %CaO,40-45wt。 %P 2 O 5,10-40重量% %ZrO 2和0.7-3.5wt。 具有磷灰石和磷酸钙锆作为主要结晶相的氟化物,玻璃相作为辅助成分,直到得到可流动的混合物。 本发明还涉及具有所述组分的骨水泥试剂盒。
    • 9. 发明申请
    • Method for the Production of a Metallic Substrate Having a Biocompatible Surface and Substrate Produced Using Same
    • 具有生物相容性表面的金属基材的制造方法及使用其生产的基材
    • US20070122638A1
    • 2007-05-31
    • US11563884
    • 2006-11-28
    • Georg BergerUte Ploska
    • Georg BergerUte Ploska
    • B32B15/04
    • A61L27/04A61L27/306Y10T428/26
    • The invention relates to a method for the production of a metallic substrate having a biocompatible surface and to the substrate that is produced by means of said method. The method comprises treatment of a metal, i.e., Ti, Ti alloys with Al, V, Ta, Nb, Ni, Fe, Mo or mixtures thereof, Ta, Ta alloys with Fe, Al, Cr, stainless steel, with a melt of calcium nitrate and an additional component which is an oxygen salt of Na, K, Li, Mg and mixtures thereof, said treatment being effected at 180-480 ° C. for 0.1 to 12 hours. A substrate is obtained, wherein the overall layer thickness ranges from 10 to below 1600 nm and the fatigue strength of the substrate is in the same fatigue strength range as that of an untreated substrate at equal number of vibrations N.
    • 本发明涉及一种生产具有生物相容性表面的金属基材和通过所述方法生产的基材的方法。 该方法包括用Al,V,Ta,Nb,Ni,Fe,Mo或其混合物处理Ti,Ti合金,与Fe,Al,Cr,不锈钢的Ta,Ta合金, 硝酸钙和作为Na,K,Li,Mg的氧盐的其它组分及其混合物,所述处理在180-480℃下进行0.1至12小时。 获得基板,其中总层厚度范围为10至1600nm以下,并且基板的疲劳强度与相同数量的振动N下的未处理基板的疲劳强度范围相同。